---
title: "Novo Nordisk’s new weight‑loss drug falls short, shares tumble"
summary: "Novo Nordisk’s next‑gen weight‑loss drug, CagriSema, lost 23% of body weight in trials versus 25.5% by Lilly’s tirzepatide, failing to meet its main goal. The study didn’t show it matched the competitor, sending Novo’s shares down 16.5% and cutting profit forecasts. The drug is still awaiting FDA approval, but its future looks uncertain."
section: "Business"
category: "Medical Research News"
imageUrl: "https://media.guim.co.uk/3e2b9b8ddb01a56e64f042658bec1cbe803db14d/430_0_2918_2335/500.jpg"
publishedAt: "2026-02-23T14:26:30Z"
guardianId: "business/2026/feb/23/wegovy-ozempic-weight-loss-drug-novo-nordisk-cagrisema"
---

Novo Nordisk’s next‑gen weight‑loss drug, CagriSema, lost 23% of body weight in trials versus 25.5% by Lilly’s tirzepatide, failing to meet its main goal. The study didn’t show it matched the competitor, sending Novo’s shares down 16.5% and cutting profit forecasts. The drug is still awaiting FDA approval, but its future looks uncertain.
